Pacira BioSciences, Inc. filed a Form 8-K on November 17, 2026, disclosing the completion of its acquisition by Viatris Inc., the termination of its credit agreement, and the execution of a supplemental indenture and capped call unwind agreements in connection with the merger.

Key Highlights

  • Merger completed: Viatris acquired Pacira BioSciences on November 17, 2026, with the company continuing as the surviving corporation and a wholly owned subsidiary of Viatris.
  • Offer price: Stockholders received $36.50 per share in cash, net of applicable withholding taxes and without interest.
  • Shares tendered: A total of 32,929,780 shares were validly tendered and not properly withdrawn, representing approximately 66.46% of issued and outstanding shares as of the Expiration Date.
  • Convertible notes: The First Supplemental Indenture, dated November 17, 2026, amends the indenture governing the company's 2.125% Convertible Senior Notes due 2029, of which $287.5 million in aggregate principal amount is outstanding.
  • Credit agreement terminated: $96,392.50, representing all amounts outstanding under the Credit Agreement with Wells Fargo Bank, National Association, was repaid in full and all commitments were terminated.
  • Capped call unwind: On November 17, 2026, the company entered into unwind agreements for each capped call confirmation, with cash payments from counterparties to the company payable on or about that date.

Viatris Completes Tender Offer and Merger with Pacira BioSciences

According to the filing, Viatris Inc. and its wholly owned subsidiary, Peach Purchaser Sub Inc., entered into a Merger Agreement with Pacira BioSciences on October 8, 2026. The tender offer commenced on October 30, 2026, at an offer price of $36.50 per share in cash. The offer expired at one minute following 11:59 p.m., Eastern Time, on November 16, 2026, and was not extended. On November 17, 2026, Viatris announced that 32,929,780 shares had been validly tendered, representing approximately 66.46% of the issued and outstanding shares, satisfying the Minimum Condition as defined in the Merger Agreement. Purchaser irrevocably accepted for payment all validly tendered shares on November 17, 2026.

Following the consummation of the offer, the merger was completed on November 17, 2026, pursuant to Section 251(h) of the Delaware General Corporation Law, without a stockholder vote. Peach Purchaser Sub Inc. was merged with and into Pacira BioSciences, with Pacira continuing as the surviving corporation and becoming a wholly owned subsidiary of Viatris.

In connection with the merger, the company and Computershare Trust Company, National Association, executed a First Supplemental Indenture dated November 17, 2026, governing the company's 2.125% Convertible Senior Notes due 2029. The filing states that the merger constitutes "a Common Stock Change Event, a Make-Whole Fundamental Change, a Fundamental Change and an Exempted Fundamental Change" with respect to the notes. From the Effective Time, the right to convert each $1,000 principal amount of notes was changed into a right to receive cash equal to $36.50 multiplied by the applicable Conversion Rate. The company disclosed it elected to rely on Section 14.05 of the indenture and will not offer to repurchase notes in connection with the merger. Separately, all outstanding amounts under the Wells Fargo credit agreement, dated July 3, 2025, totaling $96,392.50, were repaid in full and all related commitments terminated.

What Was Disclosed

Pacira BioSciences disclosed the November 17, 2026 completion of its merger with Viatris at $36.50 per share, alongside the execution of a supplemental indenture for its 2.125% Convertible Senior Notes due 2029, unwind of capped call transactions, and full termination of its Wells Fargo credit agreement.